Transcenta Holding Limited (HK:6628)
:6628
Top Page
Transcenta Holding Limited
(6628)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$2.50
▲(11.11% Upside)
Action:UpgradedDate:01/29/26
The score is primarily driven down by weak financial performance (declining revenue, sizable losses, and cash burn). Technical indicators are mixed with negative MACD and price below longer-term averages, offering only limited support. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Moderate leverage / balance sheet stability
A debt-to-equity of 0.33 signals moderate leverage, reducing short-term refinancing risk and helping preserve financial flexibility. For a biotech requiring multi-year R&D, lower leverage improves prospects to fund trials or absorb delays without immediate dilutive financing.
Negative Factors
Declining revenue and persistent losses
Steep and sustained revenue declines combined with deeply negative margins indicate the company is failing to commercialize at scale. Over months this erodes runway, constrains reinvestment in R&D/commercialization, and raises reliance on external capital, harming long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage / balance sheet stability
A debt-to-equity of 0.33 signals moderate leverage, reducing short-term refinancing risk and helping preserve financial flexibility. For a biotech requiring multi-year R&D, lower leverage improves prospects to fund trials or absorb delays without immediate dilutive financing.
Read all positive factors
Transcenta Holding Limited (6628) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.25B
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-57.84%
EPS Growth24.58%
CountryHK
Employees184
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding452,409,000
10 Day Avg. Volume1,161,500
30 Day Avg. Volume1,285,964
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.32
Price to Sales (P/S)21.27
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)HK$15.24M
Transcenta Holding Limited Business Overview & Revenue Model
Company Description
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company devel...
How the Company Makes Money
Transcenta generates revenue primarily through the development and commercialization of its biopharmaceutical products. Key revenue streams include sales from approved drugs, licensing agreements with other pharmaceutical companies, and collaborat...
Transcenta Holding Limited Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 11.26M | 53.85M | 101.89M | 50.24M | 80.98M |
| Gross Profit | 3.27M | 4.00M | 14.40M | 19.89M | 9.37M | 18.20M |
| EBITDA | -211.90M | -233.12M | -393.01M | -334.09M | -1.65B | -264.81M |
| Net Income | -266.36M | -290.29M | -462.57M | -406.75M | -1.72B | -316.63M |
Balance Sheet | ||||||
| Total Assets | 1.04B | 1.20B | 1.69B | 2.13B | 2.54B | 2.09B |
| Cash, Cash Equivalents and Short-Term Investments | 45.81M | 169.42M | 546.03M | 895.45M | 1.22B | 813.59M |
| Total Debt | 210.14M | 250.61M | 409.63M | 411.46M | 364.71M | 254.30M |
| Total Liabilities | 386.57M | 448.64M | 665.67M | 660.64M | 579.39M | 2.91B |
| Stockholders Equity | 652.13M | 751.64M | 1.03B | 1.47B | 1.97B | -816.25M |
Cash Flow | ||||||
| Free Cash Flow | -175.14M | -216.15M | -373.80M | -318.03M | -457.84M | -237.73M |
| Operating Cash Flow | -170.07M | -213.83M | -358.04M | -295.81M | -384.50M | -174.40M |
| Investing Cash Flow | 8.23M | 14.28M | 57.47M | -102.61M | -69.77M | -57.74M |
| Financing Cash Flow | -157.75M | -178.06M | -47.20M | 26.72M | 879.71M | 620.17M |
Transcenta Holding Limited Technical Analysis
Positive
2.25
Price Trends
2.33
Positive
2.43
Positive
2.83
Negative
Market Momentum
0.12
Negative
62.40
Neutral
86.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Positive. The current price of 2.25 is below the 20-day moving average (MA) of 2.41, below the 50-day MA of 2.33, and below the 200-day MA of 2.83, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 62.40 is Neutral, neither overbought nor oversold. The STOCH value of 86.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6628.
Transcenta Holding Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
52 Neutral | HK$3.70B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.30B | -4.06 | -70.71% | ― | ― | 81.67% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$717.58M | -2.18 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.25B | -2.47 | -27.44% | ― | -57.84% | 24.58% |
* Healthcare Sector Average
HK:6628
Transcenta Holding Limited
2.82
1.68
147.37%
HK:9939
Kintor Pharmaceutical Ltd
2.64
1.53
137.75%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.40
212.50%
HK:2197
Clover Biopharmaceuticals Ltd.
2.85
2.65
1325.00%
HK:2257
Sirnaomics Ltd.
6.54
3.49
114.43%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.58
49.15%
Transcenta Holding Limited Corporate Events
Transcenta Advances Dealmaking, Licensing and Financing to Resolve Audit Disclaimer and Bolster Liquidity
Jan 22, 2026
Transcenta has provided an operational update on the measures it is taking to resolve a disclaimer of opinion in its 2024 annual report, highlighting continued progress on nine key initiatives intended to strengthen its financial position and liqu...
Transcenta Grants 2 Million Incentive Shares to Key Employee Under Performance-Linked Scheme
Dec 29, 2025
Transcenta Holding Limited has granted 2,000,000 award shares, equivalent to about 0.44% of its issued share capital (excluding treasury shares), to a single employee participant under its share incentive scheme. Half of the award is tied to the a...
Transcenta Licenses HiCB Biomanufacturing Platform to EirGenix in Strategic Collaboration
Dec 29, 2025
Transcenta Holding Limited has entered into a strategic collaboration and non-exclusive licensing agreement with Taiwan-listed EirGenix Inc., under which EirGenix will adopt Transcenta’s HiCB continuous biomanufacturing platform for its biol...
Transcenta’s Osemitamab Shows Promising Results in Cancer Trial
Dec 4, 2025
Transcenta Holding Limited announced promising updated efficacy data from its phase I/II Transtar102 trial involving osemitamab combined with nivolumab and CAPOX for first-line treatment of gastric/gastroesophageal junction cancer. The trial resul...
Transcenta Announces Share and Option Grants to Boost Strategic Goals
Nov 20, 2025
Transcenta Holding Limited announced the grant of 200,000 Award Shares and 800,000 Options under its Share Incentive Scheme. The shares are granted to service providers based on performance targets related to fundraising and partnership milestones...
Transcenta Holding Limited Announces Auditor Change to Ernst & Young
Nov 12, 2025
Transcenta Holding Limited has announced a change in its auditor, with Deloitte Touche Tohmatsu resigning due to a disagreement over audit fees for the financial year ending December 31, 2025. The company has appointed Ernst Young as the new audi...
Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
Oct 30, 2025
Transcenta Holding Limited announced that its partner, Inhibrx Biosciences, has reported positive Phase 2 results for ozekibart in treating chondrosarcoma, a cancer with no approved systemic options. The promising results from the ChonDRAgon study...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.